Stemirna Therapeutics, a Chinese biotech startup specialized in RNA technology-based drug development, has entered into a staged investment agreement with Shanghai-listed domestic pharma Tibet Rhodiola Pharmaceutical that could bring the startup capital injections of up to 351 million yuan ($50 million).
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
